{"title":"BIC/FTC/TAF取得长期成功的药理学决定因素:效力、遗传屏障和宽恕。","authors":"Stefano Bonora","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"311-313"},"PeriodicalIF":1.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgiveness.\",\"authors\":\"Stefano Bonora\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.</p>\",\"PeriodicalId\":54723,\"journal\":{\"name\":\"New Microbiologica\",\"volume\":\"47 4\",\"pages\":\"311-313\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New Microbiologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Microbiologica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgiveness.
In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.
期刊介绍:
The publication, diffusion and furtherance of research and study on all aspects of basic and clinical Microbiology and related fields are the chief aims of the journal.